Anupam Rasayan India Limited Reports Q4 and FY26 Financial Results
Ravi S Chakraborty
Anupam Rasayan India Limited reported a 26% year-over-year increase in quarterly revenue to Rs 6,392 Mn for Q4FY26 compared to Rs 5,057 Mn in Q4FY25. The company's consolidated annual revenue reached Rs 23,836 Mn in FY26, marking a 65% growth from Rs 14,485 Mn in FY25. EBITDA for the full year stood at Rs 5,430 Mn, reflecting a 32% rise, while profit after tax increased to Rs 2,222 Mn, up 39% year-on-year.
Operational performance showed mixed trends in the latest quarter. EBITDA for Q4FY26 declined 6% to Rs 1,407 Mn from Rs 1,500 Mn in the same period last year, resulting in an EBITDA margin of 22%. Profit after tax for the quarter fell to Rs 560 Mn, down from Rs 629 Mn in Q4FY25. The company attributed the quarterly EBITDA decline to higher operational costs despite strong revenue growth.
Strategic developments highlight the company's expansion. Anupam Rasayan India Limited announced the acquisition of Jayhawk Fine Chemicals in the US, which contributed proforma revenue of US$ 95Mn. the company signed a definitive agreement to acquire Bliss GVS Pharma, aiming to enhance its pharmaceutical value chain and CDMO capabilities. These moves align with its focus on specialty chemicals and global market penetration.
The managing director, Mr. Anand Desai, emphasized FY26 as a landmark year for the company. He noted record annual sales, operating cash flow, and strong cash generation. Growth was driven by new product commercialization, multinational customer additions, and expansion in key verticals. The company operates eight manufacturing facilities across India and the US, with a total installed capacity of over 2,00,000 MT as of March 31, 2026.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.